Finally sofosbuvir: an oral anti-HCV drug with wide performance capability.
Finally sofosbuvir: an oral anti-HCV drug with wide performance capability.
复制标题
DOI：
10.2147/pgpm.s52629
复制
发表时间：
2014
影响因子：
1.9
通讯作者：
Schmidt WN
中科院分区：
文献类型：
--
作者：
Kayali Z;Schmidt WN
慢性丙型肝炎病毒（HCV）感染是世界范围内晚期肝病的主要原因。这种病毒成功地逃避了宿主的免疫检测，多年来阻碍了寻找一种安全、简单、可靠的口服抗病毒治疗方法的努力。最初，干扰素和利巴韦林治疗是治疗的标准护理，但它在广泛的HCV疾病中提供的效果有限，并且充满了过多的副作用，通常是有限的。Sofosbuvir （SOF）是一种有效的一流核苷抑制剂，最近已被批准用于治疗HCV。该药毒性低，耐药屏障高，与其他HCV直接作用抗病毒药物（如蛋白酶抑制剂或抗ns5a药物）的相互作用最小。SOF是安全的，可用于不同的病毒基因型、疾病阶段和特殊患者群体，如合并感染人类免疫缺陷病毒的患者。当与利巴韦林或其他直接作用的抗病毒药物联合使用时，SOF已经彻底改变了HCV治疗谱，并为几乎普遍的HCV抗病毒治疗奠定了基础。与迄今为止开发的任何其他抗hcv药物相比，SOF对所有感染患者都具有最广泛的适用性，并且新的治疗方案将被量身定制以最大限度地提高疗效。
Chronic Hepatitis C virus (HCV) infection is the leading cause of advanced liver disease worldwide. The virus successfully evades host immune detection and for many years has hampered efforts to find a safe, uncomplicated, and reliable oral antiviral therapy. Initially, interferon and ribavirin therapy was the treatment standard of care, but it offered limited performance across the wide spectrum of HCV disease and was fraught with excessive and often limiting side effects. Sofosbuvir (SOF) is a potent first-in-class nucleoside inhibitor that has recently been approved for treatment of HCV. The drug has low toxicity, a high resistance barrier, and minimal drug interactions with other HCV direct-acting antiviral agents such as protease inhibitors or anti-NS5A agents. SOF is safe and can be used across different viral genotypes, disease stages, and special patient groups, such as those coinfected with human immunodeficiency virus. When used in combination with ribavirin or another direct-acting antiviral agent, SOF has revolutionized the HCV treatment spectrum and set the stage for nearly universal HCV antiviral therapy. More so than any other anti-HCV drug developed to date, SOF offers the widest applicability for all infected patients, and new regimens will be tailored to maximize performance.